Arch Biopartners Inc. (ACHFF)
OTCMKTS · Delayed Price · Currency is USD
0.65206
+0.0321 (5.17%)
Nov 9, 2026, 2:14 PM EST
Arch Biopartners Revenue
In the fiscal year ending September 30, 2025, Arch Biopartners had annual revenue of 275.94K CAD, down -87.00%. That makes Arch Biopartners the 45,994th largest company in the world by revenue and 6,765th in the United States.
Revenue
275.94K CAD
Revenue Growth
-87.00%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
44.30M USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 275.94K | -1.85M | -87.00% |
| Sep 30, 2024 | 2.12M | 138.21K | 6.97% |
| Sep 30, 2023 | 1.98M | 1.02M | 105.63% |
| Sep 30, 2022 | 964.68K | -2.92M | -75.18% |
| Sep 30, 2021 | 3.89M | 3.82M | 5,625.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vaxart | 181.27M |
| Sangamo Therapeutics | 34.56M |
| Nuo Therapeutics | 5.20M |
| ZIVO Bioscience | 209.03K |
| Provectus Biopharmaceuticals | 57.48K |
Arch Biopartners News
- 3 days ago - Arch Biopartners Arranges Non-Brokered Private Placement - GlobeNewsWire
- 2 months ago - Arch Biopartners Receives Central IRB Approval to Support U.S. Sites in Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial of LSALT Peptide - GlobeNewsWire
- 3 months ago - Arch Biopartners Engages Private Laboratory to Accelerate IL-32 Chronic Kidney Disease Program - GlobeNewsWire
- 4 months ago - Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors - GlobeNewsWire
- 5 months ago - Arch Biopartners Featured in American Diabetes Association Thought Leadership Series at the 2026 Scientific Sessions in New Orleans - GlobeNewsWire
- 5 months ago - Arch Biopartners announces Royal Columbian Hospital has dosed its first patient in its Phase II cardiac surgery-associated AKI trial - GlobeNewsWire
- 6 months ago - Royal Columbian Hospital begins patient recruitment in Arch Biopartners' Phase II trial of LSALT peptide targeting CS-AKI - GlobeNewsWire
- 7 months ago - Arch Biopartners Closes Non-Brokered Private Placement - GlobeNewsWire